.svg){kind=small}
Mar-2026
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Stigma Grow has shown consistent performance in the Alberta market, particularly in the Capsules category, where it maintained a steady 4th place ranking from December 2025 through March 2026. This stability is noteworthy, especially considering a notable sales increase in March 2026, which suggests a strong foothold in this category. In the Concentrates category, Stigma Grow experienced some fluctuations, moving from 9th to 10th place by March 2026. Despite this slight dip in ranking, the brand's sales figures indicate a recovery in March, which may point to potential growth opportunities in the coming months.
In British Columbia, Stigma Grow's performance in Capsules saw an improvement, climbing from 7th place in December 2025 to 5th in February 2026, although it settled at 6th by March. This upward trajectory in rankings, despite a fluctuation in sales, suggests a positive reception in the market. The Concentrates category in British Columbia also saw some movement, with Stigma Grow ranking 16th in March 2026 after a brief dip to 19th in January and February. Meanwhile, in Ontario, the brand maintained a consistent 10th place in the Capsules category, demonstrating a stable presence without any upward or downward movement in rankings, which could indicate a need for strategic initiatives to climb higher in the rankings.
Competitive Landscape
In the competitive landscape of the concentrates category in Alberta, Stigma Grow has experienced some fluctuations in its ranking over the months from December 2025 to March 2026. Starting at 9th place in December 2025, Stigma Grow improved slightly to 8th in January 2026, but then slipped back to 10th in both February and March 2026. This indicates a challenge in maintaining a stable position amidst strong competition. Notably, Western Cannabis has shown a significant upward trajectory, moving from 16th in December 2025 to 9th by March 2026, even surpassing Stigma Grow in February. Meanwhile, SUGR consistently maintained a higher rank, although it experienced a decline from 4th to 8th place over the same period. Headstone Cannabis showed volatility, with rankings ranging from 12th to 8th, while HotBox (Canada) entered the top 20 in February and March, ranking 11th and 12th respectively. These dynamics suggest that while Stigma Grow remains a key player, it faces intense competition from brands like Western Cannabis and SUGR, which could impact its sales performance and market strategy moving forward.
Notable Products
In March 2026, Phoenix Tears RSO (1g) maintained its position as the top-performing product for Stigma Grow, with sales reaching 3753 units, showing a slight increase from the previous month. Indica RSO Capsules 25-Pack (250mg) also held steady at the second rank, maintaining consistent sales performance. CBD Softgels 15-Pack (750mg CBD) improved its ranking to third place, recovering from a dip in February. Phoenix Tears Honey Oil (1g) experienced a slight drop, moving from third to fourth place. Rippin Razz 2.0 Shatter (4g) remained in fifth place, consistent with its February ranking.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
